Clinical trial
Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
NCT00091793 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00091793 |
|---|---|
| Title | Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis |
| Official title | A Randomized, Double-Blind Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Postmenopausal Osteoporosis |
| Intervention type | Drug |
| Interventions | AMG 162, Placebo |
| Enrollment | 332 |
| Start date | Aug 1, 2004 |
| Primary completion | Feb 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Sep 21, 2004 |
| Last update posted | Dec 31, 2010 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: